iwCAR-T 2025 Highlights – Unleashing the Next Frontier in Immunotherapy
The 7th International Workshop on CAR-T and Bispecific Antibodies (iwCAR-T 2025) convened in Miami, Florida, bringing together global leaders in cellular immunotherapy. This premier event focused on the latest advancements in CAR-T cell therapies and bispecific antibodies, addressing challenges in both hematologic malignancies and solid tumors.
The workshop featured keynote presentations, panel discussions, and networking opportunities aimed at accelerating the development and clinical application of these innovative treatments.
Here is a compilation of notable insights shared by experts during iwCART25:
Allison Betof Warner, Director of Advanced Melanoma Program, Director of Solid Tumor Cell Therapy, Stanford Cancer Institute, shared on X:
“An entire day for solid tumor at iwCART25!
How far we’ve come in solid tumor cell therapy- 2 approvals since I was at this meeting last year! Looking forward to a great meeting.”
VJHemOnc shared on X:
“Engineering myeloid cells for solid tumors immunotherapy at iwCART25. Innovative strategies are being explored.”
Dr. Yi Lin, Professor at Mayo Clinic Comprehensive Cancer Center, reflected on X:
“Novel technologies for solid tumors session iwCART25. Can we push the envelope to get breakthrough response?
Different engineering, cell types, enhancers…”
Dr. Yi Lin also noted:
“Now delving into bispecific antibodies therapies in multiple myeloma at iwCART25. We have 3 antigen targets, dual & triple targets in clinic & trials. How best to optimize their use?
Dr Rakesh Popat starts with Cevostamab data ”
VJHemOnc reported:
“Early data on BMS-986353!
Lazaros Lekakis explores in vivo expanding anti-CD19 CAR-T for autoimmunity at iwCART25. New advancements in CAR-T therapy for autoimmune conditions!”
VJ Oncology highlighted:
“Advancing T cell therapies for solid cancers! Saul Priceman from USC discusses cutting-edge developments at iwCART25. Targeting solid tumors with next-gen T cells!”
VJHemOnc shared:
“Next at iwCART25 – Mihaela Druta from Moffitt Cancer Center discusses the latest on afamicel. How is this TCR therapy shaping the future of treatment?”
VJHemOnc also noted:
“Metabolic fitness in CAR-T!
Ciara Freeman from Moffitt Cancer Center discusses how metabolic fitness early in treatment can impact CAR-T cell efficacy at iwCART25.
Optimizing cell therapies from the start!”
VJHemOnc shared on X:
“In the 3rd keynote talk of iwCART25, Michael Hudecek (Wurzburg University) discusses advancing CAR T-cell therapy and how small molecules and next-gen CRISPR2.0 edits are supercharging cell engineering for faster, smarter cancer treatments”
Stay in the loop on global oncology conferences — follow OncoDaily.
By Md Foorquan Hashmi, MD, Sr. Editor, OncoDaily: India Bureau
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023